“The investigational product has shown promising results in phase 2b for triple negative breast cancer; and successfully progressed into clinical phase III”, says RNCOS.

Noida, UP -- (SBWire) -- 02/06/2015 --According to a new research report by RNCOS entitled, "Global Antibody Drug Conjugate Market Outlook 2018", CDX-011 is a fully human monoclonal antibody drug conjugate targeting glycoprotein non-metastatic b (GPNMB) protein. GPNMB is expressed by multiple tumor types including breast cancer and melanoma. This antibody candidate is linked to potent cytotoxic monomethyl auristatin E using Seattle's genetic proprietary technology. In 2013, Celldex Therapeutics launched a METRIC study of CDX-011 in patients with metastatic triple negative breast cancer with over expressed glycoprotein NMB. The aim of the study was to investigate the safety of CDX-011 in patients having advanced triple negative breast cancer in Phase II. The study was successful in overcoming breast cancer.

Currently, triple negative breast cancer patients have very limited options and glycoprotein NMB serves as an important biomarker for breast cancer and CDX-011 (Glembatumumab vedotin) holds significant potential to serve women suffering from triple negative breast cancer. Celldex is currently conducting a phase III trial of CDX-011 in metastatic breast cancer patients defined by 25% GPNMB expressing epithelial tumor cells with triple-negativity.

The report provides an in-depth research and rational analysis of the current status and future prospect of the Antibody Drug Conjugate market. The report analyzes the market for Adcetris and Kadcyla in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved. The report also provides an insight into the key ADCs that are currently in pipeline. A brief analysis on the types of ADCs has been done on the basis of types of drug used, clinical phases and cancers targeted.

Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided. At the end, major players of ADC market have been discussed. A brief business overview of every player has been provided alongwith their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM667.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.